Literature DB >> 7511473

Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer.

F Stiefel1, R Morant.   

Abstract

Obstructive ileus is not common, but is a very distressing syndrome in a palliative care unit. The case of a 86-year-old woman with obstructive ileus due to advanced pancreatic cancer is presented. Successful management was made possible by a new somatostatin analogue (Vapreotide), administered i.m. at weekly intervals. Vapreotide was found to reduce nausea and vomiting considerably, by inhibiting the release and action of gastrointestinal hormones and the secretory and motor functions of stomach and intestines. The role of somatostatin analogues in the management of obstructive ileus in advanced cancer is discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7511473     DOI: 10.1007/bf00326640

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  2 in total

1.  Comparison of somatostatin and its highly potent hexa- and octapeptide analogs on exocrine and endocrine pancreatic secretion.

Authors:  S J Konturek; J Bilski; J Jaworek; J Tasler; A V Schally
Journal:  Proc Soc Exp Biol Med       Date:  1988-02

2.  Somatostatin as adjuvant therapy in the management of obstructive ileus.

Authors:  E Bastounis; L Hadjinikolaou; N Ioannou; M Papastamatiou; E Toumbis; G Makri
Journal:  Hepatogastroenterology       Date:  1989-12
  2 in total
  2 in total

Review 1.  Continuing pursuit for ideal systemic anticancer radiotherapeutics.

Authors:  Marlein Miranda Cona; Huaijun Wang; Junjie Li; Yuanbo Feng; Feng Chen; Peter de Witte; Alfons Verbruggen; Yicheng Ni
Journal:  Invest New Drugs       Date:  2011-10-18       Impact factor: 3.850

2.  Why not octreotide?

Authors:  S Mercadante
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.